<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00252187</url>
  </required_header>
  <id_info>
    <org_study_id>69-00</org_study_id>
    <secondary_id>R01HL036634</secondary_id>
    <secondary_id>R01HL084155</secondary_id>
    <secondary_id>P01HL076611</secondary_id>
    <secondary_id>UL1RR024150</secondary_id>
    <nct_id>NCT00252187</nct_id>
  </id_info>
  <brief_title>Cardiac Hormone Replacement With Brain Natriuretic Peptide (BNP) in Heart Failure</brief_title>
  <acronym>SubqBNP</acronym>
  <official_title>Cardiac Hormone Replacement With BNP in Heart Failure: A Novel Therapeutic Strategy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Horng Chen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Heart Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Scios, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Center for Research Resources (NCRR)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effects of subcutaneous injection of Human BNP
      (nesiritide), a hormone produced by the heart, on the pumping ability of the heart, kidney
      function, and hormonal function in persons with heart failure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The cardiac hormone brain natriuretic peptide (BNP) plays an important role in the
      pathophysiology of congestive heart failure (CHF). Studies have established that BNP mediates
      natriuresis, renin and aldosterone (RAAS) inhibition, vasodilation and lusitropism. Acute
      cardiac hormone replacement with intravenous infusion of BNP has been shown to possess potent
      vasodilating actions in humans with acute decompensated CHF resulting in improvement of
      clinical symptoms. Natrecor (nesiritide) a sterile, purified preparation of human BNP is
      approved by the FDA for intravenous administration in the treatment of patients with acute
      decompensated congestive heart failure. However, chronic cardiac hormone replacement with BNP
      as therapeutic strategy in CHF has been limited by the need to administer BNP intravenously.
      The objective of this study is to define the cardiorenal and humoral actions of short term
      (eight weeks) chronic cardiac hormone replacement with subcutaneous (SQ) BNP in human NYHA
      class II-III CHF. Systolic and diastolic function, left ventricular remodeling as assessed by
      its volume, renal function, neurohumoral profiling and exercise capacity will be assessed
      prior to and after eight weeks of treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2000</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Left Ventricular (LV) Volume Index at 8 Weeks</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>LV volume was measured for systolic volume and diastolic volume using a cardiac Magnetic Resonance Imaging (MRI) scan. All cardiac MRI images were reviewed by an independent cardiologist in a blinded fashion.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Left Ventricular (LV) Mass Index at 8 Weeks</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Left Ventricular (LV) Filling Pressure at 8 Weeks</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Filling pressure determined by ratio of E/e' [Echocardiograph Doppler mitral inflow velocity (E) to mitral annulus tissue Doppler velocity (e') ratio]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Plasma Renin Activity at 8 Weeks</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Plasma renin is synthesized within circulation or at tissue sites, causing vasoconstriction or vasodilation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Renal Function as Measured by Glomerular Filtration Rate (GFR) at 8 Weeks</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Kidney function was measured by GFR determined by iothalamate clearance. Glomerular filtration rate describes the flow rate of filtered fluid through the kidney measured in milliliters per minute per 1.73 m^2 of body-surface area. A lower GFR means the kidney is not filtering normally.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Heart Rate at 8 Weeks</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Heart rate was measured when MRI was performed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Blood Pressure at 8 Weeks</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Blood pressure was measured during the MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Left Ventricular Ejection Fraction at 8 Weeks</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Left Ventricle Ejection Fraction (LVEF)is a clinical parameter used by cardiologists to describe how well the heart is pumping. LVEF is a measure of the amount of blood pumped out of the lower chamber (ventricle) of the heart during a heartbeat, measured by Magnetic Resonance Imaging (MRI).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Congestive Heart Failure</condition>
  <condition>Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>B-type Natriuretic Peptide (BNP)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>BNP (nesiritide) administered subcutaneously twice daily for 8 weeks at 10 mcg/kg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo self-administered subcutaneously twice daily for 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>B-type Natriuretic Peptide (BNP)</intervention_name>
    <description>BNP hormone self-administered subcutaneously twice daily for 8 weeks at 10 mcg/kg.</description>
    <arm_group_label>B-type Natriuretic Peptide (BNP)</arm_group_label>
    <other_name>Nesiritide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo self-administered subcutaneously twice daily for 8 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age &gt; 18 years

          2. Resting left ventricular ejection fraction (LVEF) of 35% or less (determined within 48
             months of recruitment by echocardiography, multiple gate acquisition scan (MUGA) or
             left ventriculogram.)

          3. New York Heart Association (NYHA) Class I (with previous symptoms of heart failure),
             Class II and III

          4. Female subjects not menopausal or surgically sterilized will need to have a negative
             pregnancy test the day before the study day and be on contraception.

        Exclusion Criteria:

          1. Myocardial infarction (MI) within 3 months of screening.

          2. Unstable angina within 14 days of screening, or any evidence of myocardial ischemia.

          3. Valvular stenosis, hypertrophic, restrictive or obstructive cardiomyopathy,
             constrictive pericarditis, primary pulmonary hypertension, or biopsy proven active
             myocarditis.

          4. Sustained ventricular tachycardia (VT) or ventricular fibrillation (V-fib) within 14
             days of screening.

          5. Second or third degree atrioventricular (AV) block without a permanent cardiac
             pacemaker.

          6. Cerebrovascular accident (CVA) within 3 months of screening, or other evidence of
             significantly compromised central nervous system (CNS) perfusion.

          7. Serum creatinine of &gt;3.0 mg/dL.

          8. Serum sodium of &lt;125 milliequivalents per decaLiter (mEq/dL) or &gt; 160 mEq/dL.

          9. Serum potassium of &lt; 3.5 mEq/dL or &gt; 5.2 mEq/dL.

         10. Serum digoxin level of &gt; 2.0 ng/ml.

         11. Systolic pressure of &lt;85 mmHg immediately prior to the first injection of study
             drug/placebo.

         12. LVEF &gt; 35% by within 24 months of screening.

         13. Unable to self-administer subcutaneous injection twice a day.

         14. Diagnosed with AIDS or known positive HIV titer.

         15. Other acute or chronic medical conditions or laboratory abnormality, which may
             increase the risks, associated with study participation or may interfere with
             interpretation of the data.

         16. Received an investigational drug within 1 month prior to dosing.

         17. Unable to undergo cardiac magnetic resonance imaging (MRI). Contraindications to MRI
             include pacemaker or defibrillator, pregnant women, atrial fibrillation or other
             arrhythmia, cerebral aneurysm clips, or severe claustrophobia.

         18. In the opinion of the investigator, is unlikely to comply with the study protocol or
             is unsuitable for any reasons.

         19. Patient in atrial fibrillation or who have a pacemaker or implantable cardioverter
             defibrillator (ICD)

         20. Hemoglobin &lt; 10g/dl.

         21. Patients with an allergy to iodine.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Horng H. Chen, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicaltrials.mayo.edu</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 10, 2005</study_first_submitted>
  <study_first_submitted_qc>November 10, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2005</study_first_posted>
  <results_first_submitted>November 20, 2012</results_first_submitted>
  <results_first_submitted_qc>December 19, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 20, 2012</results_first_posted>
  <last_update_submitted>December 19, 2012</last_update_submitted>
  <last_update_submitted_qc>December 19, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 20, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Horng Chen</investigator_full_name>
    <investigator_title>MD, Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Heart failure</keyword>
  <keyword>Natriuretic peptides</keyword>
  <keyword>B-type natriuretic peptide</keyword>
  <keyword>Kidney</keyword>
  <keyword>Nesiritide</keyword>
  <keyword>Natrecor</keyword>
  <keyword>CHF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Natriuretic Peptide, Brain</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited from May 2003 to May 2008 at the Mayo Clinic in Rochester, Minnesota.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>B-type Natriuretic Peptide (BNP)</title>
          <description>BNP (nesiritide) hormone self-administered subcutaneously twice daily for 8 weeks at 10 mcg/kg.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo self-administered subcutaneously twice daily for 8 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>B-type Natriuretic Peptide (BNP)</title>
          <description>BNP (nesiritide) hormone self-administered subcutaneously twice daily for 8 weeks at 10 mcg/kg.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo self-administered subcutaneously twice daily for 8 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
            <count group_id="B2" value="21"/>
            <count group_id="B3" value="45"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66" spread="10"/>
                    <measurement group_id="B2" value="65" spread="11"/>
                    <measurement group_id="B3" value="66" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Blood pressure</title>
          <description>Systolic blood pressure (SBP) the top number and diastolic blood pressure (DBP)the bottom number in a blood pressure reading, are measured in millimeters of mercury (mmHg) on a scale.</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Systolic blood pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="131" spread="18"/>
                    <measurement group_id="B2" value="127" spread="17"/>
                    <measurement group_id="B3" value="129" spread="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic blood pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72" spread="11"/>
                    <measurement group_id="B2" value="72" spread="14"/>
                    <measurement group_id="B3" value="72" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>New York Heart Association (NYHA) CHF Classification</title>
          <description>NYHA classifications of various stages of Congestive Heart Failure (CHF) help determine the severity. Class I-No symptoms at any level of exertion &amp; no limitation in ordinary physical activity. Class II-Mild symptoms and slight limitation during regular activity. Comfortable at rest. Class III-Noticeable limitation due to symptoms, even during minimal activity; Comfortable only at rest. Class IV-Severe limitations. Symptoms even while at rest. Note: The sum of categorized subjects will not equal the total number of participants enrolled in each arm, because only Class II &amp; III were reported.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>NYHA CHF Class II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NYHA CHF Class III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Left Ventricle Ejection Fraction (Echo)</title>
          <description>Left Ventricle Ejection Fraction (LVEF)is a clinical parameter used by cardiologists to describe how well the heart is pumping. LVEF is a measure of the amount of blood pumped out of the lower chamber (ventricle) of the heart during a heartbeat, measured by echocardiography. A normal LVEF ranges from 55-70%. A LVEF of 65, for example, means that 65% of the total amount of blood in the left ventricle is pumped out with each heartbeat.</description>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32" spread="9"/>
                    <measurement group_id="B2" value="31" spread="7"/>
                    <measurement group_id="B3" value="31" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Heart Rate</title>
          <description>Heart rate (HR) is a measure of how many times the heart beats per minute.</description>
          <units>beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65" spread="13"/>
                    <measurement group_id="B2" value="68" spread="12"/>
                    <measurement group_id="B3" value="67" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Plasma BNP</title>
          <description>B-type natriuretic peptide (BNP) is a cardiac hormone that affects cardiovascular function.</description>
          <units>picograms/milliliter</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51" lower_limit="18" upper_limit="102"/>
                    <measurement group_id="B2" value="63" lower_limit="10" upper_limit="318"/>
                    <measurement group_id="B3" value="53" lower_limit="12" upper_limit="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Glomerular Filtration Rate</title>
          <description>Glomerular Filtration Rate (GFR) is a measure of the flow rate or speed the kidney filters fluid, measured in milliliters per minute per 1.73 m^2 of body-surface area. A lower GFR means the kidney is not filtering normally. An estimated GFR of less than 60 ml/min/1.73 m^2 of body-surface area is considered to be impaired kidney function.</description>
          <units>ml/min/1.73 m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73" spread="22"/>
                    <measurement group_id="B2" value="77" spread="21"/>
                    <measurement group_id="B3" value="75" spread="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History or concomitant medical conditions</title>
          <description>Because participants may have none, one, or more than one medical history or concomitant medical condition, the sum of the history categories will not be the same as the overall number of participants in a given arm of the study.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>History of peripheral vascular diseases</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>History of chronic obstructive pulmonary disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>History of Coronary Artery Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>History of hypertension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>History of arrythmia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>History of smoking</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>History of diabetes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>History of high cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Concomitant Medication(s)</title>
          <description>The sum of subjects taking a given class of medication will not equal the overall number of participants per arm, because all subjects would possibly not be taking all medication classes.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>ACE I inhib, Angio II receptor blocker or nitrates</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Digoxin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Beta blocker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Coumadin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Antiarrhythmics</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diuretic (loop)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diuretic (thiazide)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diuretic (potassium sparing)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diuretic (Thiazide)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Left Ventricular (LV) Volume Index at 8 Weeks</title>
        <description>LV volume was measured for systolic volume and diastolic volume using a cardiac Magnetic Resonance Imaging (MRI) scan. All cardiac MRI images were reviewed by an independent cardiologist in a blinded fashion.</description>
        <time_frame>Baseline and 8 weeks</time_frame>
        <population>Per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>B-type Natriuretic Peptide (BNP)</title>
            <description>BNP (nesiritide) hormone self-administered subcutaneously twice daily for 8 weeks at 10 mcg/kg.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo self-administered subcutaneously twice daily for 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Left Ventricular (LV) Volume Index at 8 Weeks</title>
          <description>LV volume was measured for systolic volume and diastolic volume using a cardiac Magnetic Resonance Imaging (MRI) scan. All cardiac MRI images were reviewed by an independent cardiologist in a blinded fashion.</description>
          <population>Per protocol population</population>
          <units>ml/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>End-systolic LV volume index</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.2" spread="13"/>
                    <measurement group_id="O2" value="5.8" spread="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End-diastolic LV volume index</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.0" spread="15.4"/>
                    <measurement group_id="O2" value="6.1" spread="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in end systolic LV volume index compared between two groups</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in LV end diastolic volume was compared between two groups</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Left Ventricular (LV) Filling Pressure at 8 Weeks</title>
        <description>Filling pressure determined by ratio of E/e' [Echocardiograph Doppler mitral inflow velocity (E) to mitral annulus tissue Doppler velocity (e') ratio]</description>
        <time_frame>Baseline and 8 weeks</time_frame>
        <population>Per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>B-type Natriuretic Peptide (BNP)</title>
            <description>BNP (nesiritide) hormone self-administered subcutaneously twice daily for 8 weeks at 10 mcg/kg.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo self-administered subcutaneously twice daily for 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Left Ventricular (LV) Filling Pressure at 8 Weeks</title>
          <description>Filling pressure determined by ratio of E/e' [Echocardiograph Doppler mitral inflow velocity (E) to mitral annulus tissue Doppler velocity (e') ratio]</description>
          <population>Per protocol population</population>
          <units>E/e'</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.3" spread="2.5"/>
                    <measurement group_id="O2" value="1.1" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Plasma Renin Activity at 8 Weeks</title>
        <description>Plasma renin is synthesized within circulation or at tissue sites, causing vasoconstriction or vasodilation.</description>
        <time_frame>Baseline and 8 weeks</time_frame>
        <population>Per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>B-type Natriuretic Peptide (BNP)</title>
            <description>BNP (nesiritide) hormone self-administered subcutaneously twice daily for 8 weeks at 10 mcg/kg.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo self-administered subcutaneously twice daily for 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Plasma Renin Activity at 8 Weeks</title>
          <description>Plasma renin is synthesized within circulation or at tissue sites, causing vasoconstriction or vasodilation.</description>
          <population>Per protocol population</population>
          <units>nanograms per milliliter per hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.5" spread="7.1"/>
                    <measurement group_id="O2" value="2.3" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Renal Function as Measured by Glomerular Filtration Rate (GFR) at 8 Weeks</title>
        <description>Kidney function was measured by GFR determined by iothalamate clearance. Glomerular filtration rate describes the flow rate of filtered fluid through the kidney measured in milliliters per minute per 1.73 m^2 of body-surface area. A lower GFR means the kidney is not filtering normally.</description>
        <time_frame>Baseline and 8 weeks</time_frame>
        <population>Per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>B-type Natriuretic Peptide (BNP)</title>
            <description>BNP (nesiritide) hormone self-administered subcutaneously twice daily for 8 weeks at 10 mcg/kg.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo self-administered subcutaneously twice daily for 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Renal Function as Measured by Glomerular Filtration Rate (GFR) at 8 Weeks</title>
          <description>Kidney function was measured by GFR determined by iothalamate clearance. Glomerular filtration rate describes the flow rate of filtered fluid through the kidney measured in milliliters per minute per 1.73 m^2 of body-surface area. A lower GFR means the kidney is not filtering normally.</description>
          <population>Per protocol population</population>
          <units>ml/min/1.73 m^2 of body-surface area</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" spread="14.2"/>
                    <measurement group_id="O2" value="-2.8" spread="24.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.14</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Left Ventricular (LV) Mass Index at 8 Weeks</title>
        <time_frame>Baseline and 8 weeks</time_frame>
        <population>Per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>B-type Natriuretic Peptide (BNP)</title>
            <description>BNP (nesiritide) hormone self-administered subcutaneously twice daily for 8 weeks at 10 mcg/kg.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo self-administered subcutaneously twice daily for 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Left Ventricular (LV) Mass Index at 8 Weeks</title>
          <population>Per protocol population</population>
          <units>mg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.4" spread="9.8"/>
                    <measurement group_id="O2" value="6.2" spread="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.006</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Heart Rate at 8 Weeks</title>
        <description>Heart rate was measured when MRI was performed</description>
        <time_frame>Baseline and 8 weeks</time_frame>
        <population>Per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>B-type Natriuretic Peptide (BNP)</title>
            <description>BNP (nesiritide) hormone self-administered subcutaneously twice daily for 8 weeks at 10 mcg/kg.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo self-administered subcutaneously twice daily for 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Heart Rate at 8 Weeks</title>
          <description>Heart rate was measured when MRI was performed</description>
          <population>Per protocol population</population>
          <units>beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" spread="8.3"/>
                    <measurement group_id="O2" value="-0.9" spread="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Blood Pressure at 8 Weeks</title>
        <description>Blood pressure was measured during the MRI</description>
        <time_frame>Baseline and 8 weeks</time_frame>
        <population>Per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>B-type Natriuretic Peptide (BNP)</title>
            <description>BNP (nesiritide) hormone self-administered subcutaneously twice daily for 8 weeks at 10 mcg/kg.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo self-administered subcutaneously twice daily for 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Blood Pressure at 8 Weeks</title>
          <description>Blood pressure was measured during the MRI</description>
          <population>Per protocol population</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change in systolic blood pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.9" spread="22.2"/>
                    <measurement group_id="O2" value="4.5" spread="17.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in diastolic blood pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.4" spread="8.5"/>
                    <measurement group_id="O2" value="0.9" spread="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Left Ventricular Ejection Fraction at 8 Weeks</title>
        <description>Left Ventricle Ejection Fraction (LVEF)is a clinical parameter used by cardiologists to describe how well the heart is pumping. LVEF is a measure of the amount of blood pumped out of the lower chamber (ventricle) of the heart during a heartbeat, measured by Magnetic Resonance Imaging (MRI).</description>
        <time_frame>Baseline and 8 weeks</time_frame>
        <population>Per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>B-type Natriuretic Peptide (BNP)</title>
            <description>BNP (nesiritide) hormone self-administered subcutaneously twice daily for 8 weeks at 10 mcg/kg.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo self-administered subcutaneously twice daily for 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Left Ventricular Ejection Fraction at 8 Weeks</title>
          <description>Left Ventricle Ejection Fraction (LVEF)is a clinical parameter used by cardiologists to describe how well the heart is pumping. LVEF is a measure of the amount of blood pumped out of the lower chamber (ventricle) of the heart during a heartbeat, measured by Magnetic Resonance Imaging (MRI).</description>
          <population>Per protocol population</population>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="7.5"/>
                    <measurement group_id="O2" value="-1.1" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected over the 8 week study period</time_frame>
      <group_list>
        <group group_id="E1">
          <title>BPN Group</title>
          <description>BNP (nesiritide) administered subcutaneously twice daily for 8 weeks at 10 mcg/kg.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo self-administered subcutaneously twice daily for 8 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>hypotension</sub_title>
                <description>3 subjects in the BNP group developed hypotension (defined by systolic BP &lt;85 mmHg)or had symptoms of light-headedness or visual disturbances during the baseline visit in the Clinical Research Unit. All recovered w/ adjusted position &amp; fluids.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>lightheadedness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>worsening heart failure symptoms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>visual disturbances</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Lightheadedness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Shortness of Breath and Fatigue</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Loose stools</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>GI bleed prior to study drug administration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Flu-like symptoms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Choledocholithiasis</sub_title>
                <description>Gall stone in bile duct was accompanied by fever and elevated liver function test result.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Head congestion and productive cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Increased voiding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site sting/itchy</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Horng H. Chen</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>507-778-2354</phone>
      <email>chen.horng@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

